A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis.
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
The t(8;21)(q22;q22) translocation is one of the most common genetic abnormalities in acute myeloid leukemia (AML), identified in 15% of all cases of AML, including 40-50% of FAB M2 subtype and rare cases of M0, M1 and M4 subtypes. The most commonly known AML1-ETO fusion protein (full-length AML1-ETO) from this translocation has 752 amino acids and contains the N-terminal portion of RUNX1 (also known as AML1, CBFalpha2 or PEBP2alphaB), including its DNA binding domain, and almost the entire RUNX1T1 (also known as MTG8 or ETO) protein. Although alterations of gene expression and hematopoietic cell proliferation have been reported in the presence of AML1-ETO, its expression does not lead to the development of leukemia. Here, we report the identification of a previously unknown alternatively spliced isoform of the AML1-ETO transcript, AML1-ETO9a, that includes an extra exon, exon 9a, of the ETO gene. AML1-ETO9a encodes a C-terminally truncated AML1-ETO protein of 575 amino acids. Expression of AML1-ETO9a leads to rapid development of leukemia in a mouse retroviral transduction-transplantation model. More importantly, coexpression of AML1-ETO and AML1-ETO9a results in the substantially earlier onset of AML and blocks myeloid cell differentiation at a more immature stage. These results indicate that fusion proteins from alternatively spliced isoforms of a chromosomal translocation may work together to induce cancer development.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, the ETO domains that recruit corepressors are frequently deleted from the RUNX1-ETO leukemia fusion protein seen in primary AML cells.41,42”
From RUNX1 regulates corepressor interactions of PU.1 (2011) · cites this paper as [42]
Citations
Cites
The Transcriptional Landscape of the Mammalian Genome
Carninci, P., Kasukawa, T., Katayama, S., Gough, J., Frith, M. C., Maeda, N., Oyama, R., Ravasi, T., Lenhard, B., Wells, C., et al. (2005) · Science · doi:10.1126/science.1112014 · Cited by 3,499 · cited 1×
“The widespread existence of alternatively spliced forms of transcripts has only recently been recognized as a result of advances in mammalian genomic analysi”
BackgroundA clonogenic common myeloid progenitor that gives rise to all myeloid lineages
Akashi, K., Traver, D., Miyamoto, T., & Weissman, I. L. (2000) · Nature · doi:10.1038/35004599 · Cited by 2,617 · cited 1×
“We performed hematopoietic progenitor population analysis in leukemic mice with multicolor staining as described previousl”
MethodIdentification of Clonogenic Common Lymphoid Progenitors in Mouse Bone Marrow
Kondo, M., Weissman, I. L., & Akashi, K. (1997) · Cell · doi:10.1016/s0092-8674(00)80453-5 · Cited by 2,253 · cited 1×
“We performed hematopoietic progenitor population analysis in leukemic mice with multicolor staining as described previousl”
MethodPear, W. S., Miller, J. P., Xu, L., Pui, J. C., Soffer, B., Quackenbush, R. C., Pendergast, A. M., Bronson, R., Aster, J. C., Scott, M. L., et al. (1998) · Blood · doi:10.1182/blood.v92.10.3780 · Cited by 755
Miyoshi, H., Kozu, T., Shimizu, K., Enomoto, K., Maseki, N., Kaneko, Y., Kamada, N., & Ohki, M. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb05933.x · Cited by 498
Higuchi, M., O'Brien, D., Kumaravelu, P., Lenny, N., Yeoh, E.-J., & Downing, J. R. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00016-8 · Cited by 440 · cited 1×
“It is well known that the commonly studied full-length AE protein is not sufficient to induce leukemia in either human or mouse hematopoietic cell”
BackgroundYuan, Y., Zhou, L., Miyamoto, T., Iwasaki, H., Harakawa, N., Hetherington, C. J., Burel, S. A., Lagasse, E., Weissman, I. L., Akashi, K., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171321298 · Cited by 431 · cited 1×
“Full-length AML1-ETO is specifically expressed in myeloid cells under the control of the MRP8 promoter in MRP8-AE transgenic mic”
BackgroundSelf-citationBethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice
Kogan, S. C., Ward, J. M., Anver, M. R., Berman, J. J., Brayton, C., Cardiff, R. D., Carter, J. S., de Coronado, S., Downing, J. R., Fredrickson, T. N., et al. (2002) · Blood · doi:10.1182/blood.v100.1.238 · Cited by 418 · cited 1×
“According to the classification of the hematopathology subcommittee of the Mouse Model of Human Cancers Consortium (MMHCC”
MethodOkuda, T., Cai, Z., Yang, S., Lenny, N., Lyu, C.-J., van Deursen, J. M. A., Harada, H., & Downing, J. R. (1998) · Blood · doi:10.1182/blood.v91.9.3134 · Cited by 372
The t(8;21) Fusion Protein Interferes with AML-1B-Dependent Transcriptional Activation
Meyers, S., Lenny, N., & Hiebert, S. W. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.4.1974 · Cited by 368
Cited by
Function of alternative splicing
Stamm, S., Ben-Ari, S., Rafalska, I., Tang, Y., Zhang, Z., Toiber, D., Thanaraj, T. A., & Soreq, H. (2005) · Gene · doi:10.1016/j.gene.2004.10.022 · Cited by 1,377
Function of alternative splicing
Kelemen, O., Convertini, P., Zhang, Z., Wen, Y., Shen, M., Falaleeva, M., & Stamm, S. (2013) · Gene · doi:10.1016/j.gene.2012.07.083 · Cited by 743
Polycomb group proteins: navigators of lineage pathways led astray in cancer
Bracken, A. P., & Helin, K. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2736 · Cited by 523
Role of RUNX1 in hematological malignancies
Sood, R., Kamikubo, Y., & Liu, P. (2017) · Blood · doi:10.1182/blood-2016-10-687830 · Cited by 494
“Consequently, NF-kB signaling was activated in RUNX1CBFA2T1 cells.66 Dysregulation of tumor suppressors has been observed in RUNX1RUNX1T1 leukemia. p14ARF (CDKN2A) and NF1 expression were transcriptionally repressed through dominant inhibition of RUNX1 function.67,68 Antiapoptosis genes BCL2 and Bcl-xL are also direct…”
BackgroundInfluentialAnti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia
Glaser, S. P., Lee, E. F., Trounson, E., Bouillet, P., Wei, A., Fairlie, W. D., Izon, D. J., Zuber, J., Rappaport, A. R., Herold, M. J., et al. (2012) · Genes & Development · doi:10.1101/gad.182980.111 · Cited by 423
“…involving the Mll (mixed-lineage leukemia) gene (MLL-ENL and MLL-AF9, particularly found in infants or individuals that had previously been treated with topoisomerase inhibitors) (Ayton et al. 2004) or Aml1 gene (AML1-ETO9, found in ;15% of human AML cases) (Yan et al. 2006; Jiao et al. 2009).”
BackgroundMethodInfluentialShen, C., Sheng, Y., Zhu, A. C., Robinson, S., Jiang, X., Dong, L., Chen, H., Su, R., Yin, Z., Li, W., et al. (2020) · Cell Stem Cell · doi:10.1016/j.stem.2020.04.009 · Cited by 373
Mouse models of human AML accurately predict chemotherapy response
Zuber, J., Radtke, I., Pardee, T. S., Zhao, Z., Rappaport, A. R., Luo, W., McCurrach, M. E., Yang, M.-M., Dolan, M. E., Kogan, S. C., et al. (2009) · Genes & Development · doi:10.1101/gad.1771409 · Cited by 279
Inhibitory receptors bind ANGPTLs and support blood stem cells and leukaemia development
Zheng, J., Umikawa, M., Cui, C., Li, J., Chen, X., Zhang, C., Huynh, H., Kang, X., Silvany, R., Wan, X., et al. (2012) · Nature · doi:10.1038/nature11095 · Cited by 275
“The manufacturers and catalogue numbers for other antibodies are as follows: anti-LILRB1, Biolegend (33707); anti-LILRB2, eBioscience (125149); anti-LILRB3, eBioscience (12-5159); anti-LILRB4, eBiosciene (12-5139); anti-LILRB5, R&D Systems (AF3065); anti-PIRB–PE, R&D Systems (FAB2754P); anti-human LAIR1–PE, BD Pharmin…”
BackgroundRasmussen, K. D., Jia, G., Johansen, J. V., Pedersen, M. T., Rapin, N., Bagger, F. O., Porse, B. T., Bernard, O. A., Christensen, J., & Helin, K. (2015) · Genes & Development · doi:10.1101/gad.260174.115 · Cited by 270
“S1B; Yan et al. 2006).”
MethodThe genomic landscape of core-binding factor acute myeloid leukemias
Faber, Z. J., Chen, X., Gedman, A. L., Boggs, K., Cheng, J., Ma, J., Radtke, I., Chao, J.-R., Walsh, M. P., Song, G., et al. (2016) · Nature Genetics · doi:10.1038/ng.3709 · Cited by 269
The Leukemogenicity of AML1-ETO Is Dependent on Site-Specific Lysine Acetylation
Wang, L., Gural, A., Sun, X.-J., Zhao, X., Perna, F., Huang, G., Hatlen, M. A., Vu, L., Liu, F., Xu, H., et al. (2011) · Science · doi:10.1126/science.1201662 · Cited by 242
Kang, X., Kim, J., Deng, M., John, S., Chen, H., Wu, G., Phan, H., & Zhang, C. C. (2016) · Cell Cycle · doi:10.1080/15384101.2015.1121324 · Cited by 206
Höckendorf, U., Yabal, M., Herold, T., Munkhbaatar, E., Rott, S., Jilg, S., Kauschinger, J., Magnani, G., Reisinger, F., Heuser, M., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.06.002 · Cited by 199
Zhou, G.-B., Kang, H., Wang, L., Gao, L., Liu, P., Xie, J., Zhang, F.-X., Weng, X.-Q., Shen, Z.-X., Chen, J., et al. (2007) · Blood · doi:10.1182/blood-2006-06-032250 · Cited by 196
Self-citationAML1-ETO requires enhanced C/D box snoRNA/RNP formation to induce self-renewal and leukaemia
Zhou, F., Liu, Y., Rohde, C., Pauli, C., Gerloff, D., Köhn, M., Misiak, D., Bäumer, N., Cui, C., Göllner, S., et al. (2017) · Nature Cell Biology · doi:10.1038/ncb3563 · Cited by 187
RUNX1 and RUNX1-ETO: roles in hematopoiesis and leukemogenesis
Lam, K. (2012) · Frontiers in Bioscience · doi:10.2741/3977 · Cited by 167
“Indeed, this RUNX1-ETO9a splice isoform rapidly induces leukemia in this mouse model (142).”
BackgroundInfluentialMETTL16 drives leukemogenesis and leukemia stem cell self-renewal by reprogramming BCAA metabolism
Han, L., Dong, L., Leung, K., Zhao, Z., Li, Y., Gao, L., Chen, Z., Xue, J., Qing, Y., Li, W., et al. (2023) · Cell Stem Cell · doi:10.1016/j.stem.2022.12.006 · Cited by 159
Self-citationGozdecka, M., Meduri, E., Mazan, M., Tzelepis, K., Dudek, M., Knights, A. J., Pardo, M., Yu, L., Choudhary, J. S., Metzakopian, E., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0114-z · Cited by 162
A stable transcription factor complex nucleated by oligomeric AML1–ETO controls leukaemogenesis
Sun, X.-J., Wang, Z., Wang, L., Jiang, Y., Kost, N., Soong, T. D., Chen, W.-Y., Tang, Z., Nakadai, T., Elemento, O., et al. (2013) · Nature · doi:10.1038/nature12287 · Cited by 159
Al-Matary, Y. S., Botezatu, L., Opalka, B., Hones, J. M., Lams, R. F., Thivakaran, A., Schutte, J., Koster, R., Lennartz, K., Schroeder, T., et al. (2016) · Haematologica · doi:10.3324/haematol.2016.143180 · Cited by 155
“While AML1-ETO9a-induced AML is associated with a rather good prognosis, MLL-AF9-driven AML has a rather bad prognosis.(34,35) To study the role of monocytes/macrophages in AML, we transduced lineage negative (Lin) BM cells from WT mice with retroviruses encoding MLL-AF9 or AML1-ETO9a cDNA fused to an IRES-GFP gene ca…”
MethodMolecular mechanisms of ETS transcription factor-mediated tumorigenesis
Kar, A., & Gutierrez‐Hartmann, A. (2013) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2013.838202 · Cited by 169
“The presence of other splice variants of AML1-ETO (AML1-ETO9a) that impair co-repressor binding and deregulate cell cycle progression also accelerates the leukemogenic potential (Peterson et al., 2007; Yan et al., 2006).”
BackgroundLu, Z., Xie, J., Wu, G., Shen, J., Collins, R., Chen, W., Kang, X., Luo, M., Zou, Y., Huang, L. J.-S., et al. (2017) · Nature Medicine · doi:10.1038/nm.4252 · Cited by 139
The ITIM-containing receptor LAIR1 is essential for acute myeloid leukaemia development
Kang, X., Lu, Z., Cui, C., Deng, M., Fan, Y., Dong, B., Han, X., Xie, F., Tyner, J. W., Coligan, J. E., et al. (2015) · Nature Cell Biology · doi:10.1038/ncb3158 · Cited by 138
miR-22 has a potent anti-tumour role with therapeutic potential in acute myeloid leukaemia
Jiang, X., Hu, C., Arnovitz, S., Bugno, J., Yu, M., Zuo, Z., Chen, P., Huang, H., Ulrich, B. C., Gurbuxani, S. K., et al. (2016) · Nature Communications · doi:10.1038/ncomms11452 · Cited by 156
Self-citationBots, M., Verbrugge, I., Martin, B. P., Salmon, J. M., Ghisi, M., Baker, A., Stanley, K., Shortt, J., Ossenkoppele, G. J., Zuber, J., et al. (2014) · Blood · doi:10.1182/blood-2013-03-488114 · Cited by 133
Addiction of t(8;21) and inv(16) Acute Myeloid Leukemia to Native RUNX1
Ben-Ami, O., Friedman, D., Leshkowitz, D., Goldenberg, D., Orlovsky, K., Pencovich, N., Lotem, J., Tanay, A., & Groner, Y. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.08.020 · Cited by 132
C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice
Wang, Y., Zhao, L., Wu, C., Liu, P., Shi, L., Liang, Y., Xiong, S.-M., Mi, J., Chen, Z., Ren, R., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1019625108 · Cited by 135
“Moreover, ectopically expression of AE9a (a C-terminally truncated variant of AE) can induce AML in mice (10).”
BackgroundSelf-citationPattabiraman, D. R., McGirr, C., Shakhbazov, K., Barbier, V., Krishnan, K., Mukhopadhyay, P., Hawthorne, P., Trezise, A., Ding, J., Grimmond, S. M., et al. (2014) · Blood · doi:10.1182/blood-2012-02-413187 · Cited by 126
Mutant ASXL1 cooperates with BAP1 to promote myeloid leukaemogenesis
Asada, S., Goyama, S., Inoue, D., Shikata, S., Takeda, R., Fukushima, T., Yonezawa, T., Fujino, T., Hayashi, Y., Kawabata, K. C., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05085-9 · Cited by 125
Shia, W.-J., Okumura, A. J., Yan, M., Sarkeshik, A., Lo, M.-C., Matsuura, S., Komeno, Y., Zhao, X., Nimer, S. D., Yates, J. R., et al. (2012) · Blood · doi:10.1182/blood-2011-04-347476 · Cited by 124
“MigR1-HA-AE9a and MigR1-FLAG-AEtr vectors were previously described.(26) The cDNA of human AE9a was subcloned into p3xFLAG-CMV-7.”
BackgroundMethodSelf-citationBullinger, L., Rücker, F. G., Kurz, S., Du, J., Scholl, C., Sander, S., Corbacioglu, A., Lottaz, C., Krauter, J., Fröhling, S., et al. (2007) · Blood · doi:10.1182/blood-2006-10-049783 · Cited by 128
Martinez-Soria, N., McKenzie, L., Draper, J. E., Ptasinska, A., Issa, H., Potluri, S., Blair, H. J., Pickin, A., Isa, A., Chin, P. S., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.08.015 · Cited by 123
“ChIP experiments with RUNX1/ETO9a in KIT-positive hematopoietic stem and progenitor cells showed binding of the truncated protein to the corresponding murine Ccnd2 and Cdk6 cis-elements as shown for the full-length RUNX1/ETO protein in human cells (Figures S7I and S7J).”
BackgroundLiu, Y., Chen, W., Gaudet, J., Cheney, M. D., Roudaia, L., Cierpicki, T., Klet, R. C., Hartman, K. L., Laue, T. M., Speck, N. A., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.04.010 · Cited by 135
“In fact, the truncated AML1/ETO was more highly leukemogenic than the fulllength protein and could cooperate with full-length AML1/ ETO to induce a rapid disease (Yan et al., 2004, 2006).”
BackgroundA role for RUNX1 in hematopoiesis and myeloid leukemia
Ichikawa, M., Yoshimi, A., Nakagawa, M. M., Nishimoto, N., Watanabe‐Okochi, N., & Kurokawa, M. (2013) · International Journal of Hematology · doi:10.1007/s12185-013-1347-3 · Cited by 144
PRMT4 Blocks Myeloid Differentiation by Assembling a Methyl-RUNX1-Dependent Repressor Complex
Vu, L. P., Perna, F., Wang, L., Voza, F., Figueroa, M. E., Tempst, P., Erdjument-Bromage, H., Gao, R., Chen, S., Paietta, E., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.11.025 · Cited by 114
“Knockdown of PRMT4 reduces the leukemia burden in vivo To investigate the in vivo role of PRMT4 in leukemogenesis, we used shRNA expressing lentiviruses to knock down PRMT4 in the AML1-ETO9a (AE9a) driven mouse AML model (Yan et al., 2006; Wang et al., 2011).”
TET2-mediated mRNA demethylation regulates leukemia stem cell homing and self-renewal
Li, Y., Xue, M., Deng, X., Dong, L., Nguyen, L. X. T., Ren, L., Han, L., Li, C., Xue, J., Zhao, Z., et al. (2023) · Cell Stem Cell · doi:10.1016/j.stem.2023.07.001 · Cited by 110
Self-citationPeterson, L. F., Boyapati, A., Ahn, E.-Y. E., Biggs, J. R., Okumura, A. J., Lo, M., Yan, M., & Zhang, D. (2007) · Blood · doi:10.1182/blood-2006-11-019265 · Cited by 135
Self-citationOverexpression and knockout of miR-126 both promote leukemogenesis
Li, Z., Chen, P., Su, R. J., Li, Y., Hu, C., Wang, Y., Arnovitz, S., He, M., Gurbuxani, S. K., Zuo, Z., et al. (2015) · Blood · doi:10.1182/blood-2015-04-639062 · Cited by 112
Self-citationGao, X., Lin, J., Ning, Q., Gao, L., Yao, Y., Zhou, J., Li, Y., Wang, L.-L., & Yu, L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055481 · Cited by 113
“A total of 1610(6) viable cryopreserved primary leukemia cells from AML1-ETO9a (AE9a) transgenic leukemia mice [17] (gifted by Shanghai Institute of Hematology, Shanghai, China) were injected into the tail vein of a C57BL/6 mouse.”
BackgroundYan, F., Shen, N., Pang, J. X., Zhang, Y. W., Rao, E. Y., Bode, A. M., Al-Kali, A., Zhang, D. E., Litzow, M. R., Li, B., et al. (2017) · Leukemia · doi:10.1038/leu.2016.349 · Cited by 102
Self-citationHIF-1α can act as a tumor suppressor gene in murine acute myeloid leukemia
Velasco-Hernandez, T., Hyrenius-Wittsten, A., Rehn, M., Bryder, D., & Cammenga, J. (2014) · Blood · doi:10.1182/blood-2014-04-567065 · Cited by 101
“AE9a, which is a truncated version of the t(8;21) product AML1-ETO, has been shown to induce AML in a murine transduction/transplantation model.(23) To test whether AE9ainduced AML initiation/progression depends on HIF-1a signaling, hematopoietic stem and progenitor cells (HSPCs) (c-kit(1) cells) from Hif-1a;Mx1-Cre o…”
BackgroundMethodResultInfluentialReikvam, H., Hatfield, K. J., Kittang, A. O., Hovland, R., & Bruserud, Ø. (2011) · BioMed Research International · doi:10.1155/2011/104631 · Cited by 112
“(i) The AML1-ETO9a variant includes the alternative ETO9a exon and results in a truncated molecule of 575 amino acids that lacks the NHR3 and NHR4 domains [66, 67].”
BackgroundTargeting of AML1-ETO in t(8;21) Leukemia by Oridonin Generates a Tumor Suppressor–Like Protein
Zhen, T., Wu, C., Liu, P., Wu, H., Zhou, G., Lu, Y., Liu, J., Liang, Y., Li, K. K., Wang, Y., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003562 · Cited by 97
Self-citationChen, M., Zhu, N., Liu, X., Laurent, B., Tang, Z., Eng, R., Shi, Y., Armstrong, S. A., & Roeder, R. G. (2015) · Genes & Development · doi:10.1101/gad.267278.115 · Cited by 108
“AE9a is a spliced AE isoform that, in contrast to fulllength AE, promotes leukemia in a mouse model without secondary mutations (Yan et al. 2006).”
InfluentialAML1/ETO cooperates with HIF1α to promote leukemogenesis through DNMT3a transactivation
Gao, X., Yan, F., Lin, J., Gao, L., Lu, X., Wei, S., Shen, N., Pang, J. X., Ning, Q., Komeno, Y., et al. (2015) · Leukemia · doi:10.1038/leu.2015.56 · Cited by 101
Self-citationDayyani, F., Wang, J., Yeh, J.-R. J., Ahn, E.-Y. E., Tobey, E. M., Zhang, D., Bernstein, I. D., Peterson, R. T., & Sweetser, D. A. (2008) · Blood · doi:10.1182/blood-2007-07-103291 · Cited by 100
Self-citationFOXM1 regulates leukemia stem cell quiescence and survival in MLL-rearranged AML
Sheng, Y., Yu, C., Liu, Y., Hu, C., Ma, R., Lu, X., Ji, P., Chen, J., Mizukawa, B. E., Huang, Y., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14590-9 · Cited by 96
MLL-AF9– and HOXA9-mediated acute myeloid leukemia stem cell self-renewal requires JMJD1C
Zhu, N., Chen, M., Eng, R., DeJong, J., Sinha, A. U., Rahnamay, N. F., Koche, R. P., Al‐Shahrour, F., Minehart, J. C., Chen, C.-W. D., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci82978 · Cited by 91
“As a control, we performed CFC assays with BM cells transformed with AML1-ETO9a (48), which does not express HOXA9.”
MethodAML1/Runx1 Negatively Regulates Quiescent Hematopoietic Stem Cells in Adult Hematopoiesis
Ichikawa, M., Goyama, S., Asai, T., Kawazu, M., Nakagawa, M., Takeshita, M., Chiba, S., Ogawa, S., & Kurokawa, M. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.7.4402 · Cited by 83
CARM1 Is Essential for Myeloid Leukemogenesis but Dispensable for Normal Hematopoiesis
Greenblatt, S. M., Man, N., Hamard, P.-J., Asai, T., Karl, D. L., Martínez, C., Bilbao, D., Stathias, V., Jermakowicz, A. M., Duffort, S., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.05.007 · Cited by 87
“As AE is not fully leukemogenic in retroviral transduction and transplantation (RTT) models, we used an alternatively spliced isoform AML1-ETO exon 9a (AE9a), which lacks the NHR3 and NHR4 domains of ETO but is leukemogenic (Yan et al., 2006).”
Runx2 regulates survivin expression in prostate cancer cells
Lim, M. A., Zhong, C., Yang, S., Bell, A. M., Cohen, M. B., & Roy‐Burman, P. (2009) · Laboratory Investigation · doi:10.1038/labinvest.2009.128 · Cited by 81
“The expression of AML1-ETO was confirmed by semiquantitative RT-PCR following a reported procedure.(24) The primers used were the following: forward, AML1-ES: 50GAGGGAAAAGCTTCACTCTG-30 and reverse, ETO-EA: 50TCGGGTGAAATGTCATTGCC-30, and the thermocycle setup included denaturation at 95C1 for 30 s, annealing at 58C1 fo…”
MethodJAM3 maintains leukemia-initiating cell self-renewal through LRP5/AKT/β-catenin/CCND1 signaling
Zhang, Y., Xia, F., Liu, X., Yu, Z., Xie, L., Liu, L., Chen, C., Jiang, H., Hao, X., He, X., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci93198 · Cited by 78
“to transform hematopoietic stem/progenitor cells (33, 34).”
MethodAML1-ETO driven acute leukemia: insights into pathogenesis and potential therapeutic approaches
Hatlen, M. A., Wang, L., & Nimer, S. D. (2012) · Frontiers of Medicine · doi:10.1007/s11684-012-0206-6 · Cited by 81
“5 fetal liver cells from MRP8-AE transgenic mice were transduced with the AML1-ETO9a cDNA (Migr1-AE9a) construct and transplanted into lethally irradiated C57BL/6 recipients - The majority of the mice developed acute myeloid leukemia 5 weeks post-transplantation - The eGFP LinSca-1c-Kit, as well as the eGFP LinSca-1 c…”
BackgroundMethodInfluentialLehnertz, B., Zhang, Y. W., Boivin, I., Mayotte, N., Tomellini, E., Chagraoui, J., Lavallée, V., Hébert, J., & Sauvageau, G. (2017) · Blood · doi:10.1182/blood-2017-03-774653 · Cited by 81
Definition of a small core transcriptional circuit regulated by AML1-ETO
Stengel, K. R., Ellis, J. D., Spielman, C., Bomber, M. L., & Hiebert, S. W. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.12.005 · Cited by 75
Mechanism for ubiquitylation of the leukemia fusion proteins AML1‐ETO and PML‐RARα
Krämer, O. H., Müller, S., Buchwald, M., Reichardt, S., & Heinzel, T. (2007) · The FASEB Journal · doi:10.1096/fj.06-8050com · Cited by 72
“reported that a truncated variant of AML1-ETO that does not interact with corepressors promotes leukemia development (44).”
BackgroundJiao, B., Wu, C.-F., Liang, Y., Chen, H.-M., Xiong, S.-M., Chen, B., Shi, J.-Y., Wang, Y.-Y., Wang, J., Chen, Y., et al. (2009) · Leukemia · doi:10.1038/leu.2009.104 · Cited by 72
“Coexpression of AML1-ETO and AML1-ETO9a results in the substantially earlier onset of AML and blocks myeloid cell differentiation at a more immature stage”
BackgroundSelf-citationGardini, A., Cesaroni, M., Luzi, L., Okumura, A. J., Biggs, J. R., Minardi, S. P., Venturini, E., Zhang, D., Pelicci, P. G., & Alcalay, M. (2008) · PLoS Genetics · doi:10.1371/journal.pgen.1000275 · Cited by 78
“An alternatively spliced isoform, AML1/ ETO9a, isolated from AML patients bearing t(8;21), is instead strongly leukemogenic in mice [10].”
BackgroundSelf-citationOravecz-Wilson, K. I., Philips, S. T., Yilmaz, Ö. H., Ames, H. M., Li, L., Crawford, B. D., Gauvin, A. M., Lucas, P. C., Sitwala, K., Downing, J. R., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.06.007 · Cited by 59
“For instance, retroviral overexpression of A/E in hematopoietic cells leads to the formation of acute leukemias in some cases but not in others, and this variability might be due, in part, to expression of different isoforms (Yan et al., 2006).”
Core binding factor at the crossroads: Determining the fate of the HSC
Link, K. A., Chou, F., & Mulloy, J. C. (2009) · Journal of Cellular Physiology · doi:10.1002/jcp.21950 · Cited by 70
“An in vivo leukemia model of AML generated by an alternatively spliced form of the fusion gene, AML1-ETO9a (lacking the NHR3 and four regions), also relies on this domain to initiate leukemia (Yan et al., 2006, 2009).”
BackgroundASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia
Micol, J.-B., Pastore, A., Inoue, D., Duployez, N., Kim, E., Lee, S. C.-W., Durham, B. H., Chung, Y. R., Cho, H., Zhang, X. J., et al. (2017) · Nature Communications · doi:10.1038/ncomms15429 · Cited by 69
Posttranslational modifications of RUNX1 as potential anticancer targets
Goyama, S., Huang, G., Kurokawa, M., & Mulloy, J. C. (2014) · Oncogene · doi:10.1038/onc.2014.305 · Cited by 75
Targeted inhibition of STAT/TET1 axis as a therapeutic strategy for acute myeloid leukemia
Jiang, X., Hu, C., Ferchen, K., Nie, J., Cui, X., Chen, C.-H., Cheng, L., Zuo, Z., Seibel, W., He, C., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-02290-w · Cited by 68
Self-citationInvariant phenotype and molecular association of biallelic TET2 mutant myeloid neoplasia
Awada, H. K., Nagata, Y., Goyal, A., Asad, M., Patel, B. J., Hirsch, C. M., Kuzmanovic, T., Guan, Y., Przychodzen, B. P., Aly, M. M., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018024216 · Cited by 74
Nagata, Y., Makishima, H., Kerr, C. M., Przychodzen, B. P., Aly, M. M., Goyal, A., Awada, H. K., Asad, M., Kuzmanovic, T., Suzuki, H., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13001-y · Cited by 71
Li, C., Dong, L., Su, R. J., Bi, Y., Qing, Y., Deng, X., Zhou, Y., Hu, C., Yu, M., Huang, H., et al. (2019) · Haematologica · doi:10.3324/haematol.2018.208835 · Cited by 66
MicroRNA programs in normal and aberrant stem and progenitor cells
Arnold, C. P., Tan, R., Zhou, B., Yue, S.-B., Schaffert, S., Biggs, J. R., Doyonnas, R., Lo, M.-C., Perry, J. M., Renault, V. M., et al. (2011) · Genome Research · doi:10.1101/gr.111385.110 · Cited by 65
“Finally, we examined how miRNA expression was altered by various genetic perturbations, including loss of PTEN or Rb family genes in HSCs, ectopic expression of AML1-ETO9a in HSCs, and the MLL-AF10 transformation (de Guzman et al. 2002; Yan et al. 2006; Zhang et al. 2006; Viatour et al. 2008; Somervaille et al. 2009).”
BackgroundMethodInfluentialSelf-citationMolecular pathogenesis of core binding factor leukemia: current knowledge and future prospects
Goyama, S., & Mulloy, J. C. (2011) · International Journal of Hematology · doi:10.1007/s12185-011-0858-z · Cited by 84
“AML1ETO9a lacks NHR3 and 4 domains, and similar to the above mutant, has a strong leukemogenic potential [74].”
BackgroundCore-binding factor acute myeloid leukemia: can we improve on HiDAC consolidation?
Paschka, P., & Döhner, K. (2013) · Hematology · doi:10.1182/asheducation-2013.1.209 · Cited by 75
Complementing mutations in core binding factor leukemias: from mouse models to clinical applications
Müller, A. M. S., Duque‐Afonso, J., Shizuru, J. A., & Lübbert, M. (2008) · Oncogene · doi:10.1038/onc.2008.196 · Cited by 80
“More importantly, the coexpression of the fulllength AML1-ETO and its truncated form resulted in a substantially earlier onset of AML and blocked myeloid cell differentiation at a more immature stage (Yan et al., 2006).”
BackgroundHaploinsufficient tumor suppressor genes.
Inoue, K., & Fry, E. A. (2017) · PubMed · Cited by 85
RUNX1 regulates corepressor interactions of PU.1
Hu, Z., Gu, X., Baraoidan, K., Ibanez, V., Sharma, A., Kadkol, S., Munker, R., Ackerman, S., Nucifora, G., & Saunthararajah, Y. (2011) · Blood · doi:10.1182/blood-2010-10-312512 · Cited by 63
JMJD3 facilitates C/EBPβ-centered transcriptional program to exert oncorepressor activity in AML
Yu, S., Zhu, K.-Y., Chen, J., Liu, X.-Z., Xu, P., Zhang, W., Li, Y., Guo, H., & Zhu, J. (2018) · Nature Communications · doi:10.1038/s41467-018-05548-z · Cited by 67
Nakagawa, M. M., Shimabe, M., Watanabe‐Okochi, N., Arai, S., Yoshimi, A., Shinohara, A., Nishimoto, N., Kataoka, K., Sato, T., Kumano, K., et al. (2011) · Blood · doi:10.1182/blood-2010-12-326710 · Cited by 69
SIAH proteins: critical roles in leukemogenesis
Krämer, O. H., Stauber, R. H., Bug, G., Hartkamp, J., & Knauer, S. K. (2012) · Leukemia · doi:10.1038/leu.2012.284 · Cited by 64
CBFβ is critical for AML1-ETO and TEL-AML1 activity
Roudaia, L., Cheney, M. D., Manuylova, E., Chen, W., Morrow, M., Park, S., Lee, C.-T., Kaur, P., Williams, O., Bushweller, J. H., et al. (2009) · Blood · doi:10.1182/blood-2008-03-147207 · Cited by 59
Lin, S., Mulloy, J. C., & Goyama, S. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-3233-2_11 · Cited by 60
Transcription Factor RBPJ as a Molecular Switch in Regulating the Notch Response
Giaimo, B. D., Gagliani, E. K., Kovall, R. A., & Borggrefe, T. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-55031-8_2 · Cited by 63
TAF1 plays a critical role in AML1-ETO driven leukemogenesis
Xu, Y., Man, N., Karl, D. L., Martínez, C., Liu, F., Sun, J., Martinez, C., Martín, G. M., Beckedorff, F., Lai, F., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12735-z · Cited by 68
Man, N., Tan, Y., Sun, X., Liu, F., Cheng, G., Greenblatt, S. M., Martinez, C., Karl, D. L., Ando, K., Sun, M., et al. (2017) · Blood · doi:10.1182/blood-2016-10-745034 · Cited by 57
“Some mouse models of AE-driven AML have been developed, such as expression of AE in Cdkn1a-null hematopoietic stem cells (HSCs) or expression of AML1-ETO9a (AE9a), an alternatively spliced variant of AML1-ETO, in wild-type (WT) HSCs, which leads to fully penetrant AML after a prolonged latency.(7,8) Our recent studies…”
BackgroundOsman, D., Gobert, V., Ponthan, F., Heidenreich, O. T., Haenlin, M., & Waltzer, L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0902449106 · Cited by 60
“The C-terminal region of ETO exhibits a high PEST score, it is therefore tempting to speculate that calpains might cleave AML1-ETO to generate a proteolytic fragment similar to AML1-ETO9, a more potent inducer of leukemia than full length AML1-ETO (37).”
BackgroundBone marrow inflammation in haematological malignancies
de Jong, M. M. E., Chen, L., Raaijmakers, M. H. G. P., & Cupedo, T. (2024) · Nature reviews. Immunology · doi:10.1038/s41577-024-01003-x · Cited by 54
“Mouse HSCs are transduced with the AML1-ETO fusion oncoprotein, associated with translocation t(8;21) in patients 225 , and transplanted into lethally irradiated recipient mice that will rapidly develop a severe leukaemia resembling human AML 226 .”
Elagib, K. E., & Goldfarb, A. N. (2006) · Cancer Letters · doi:10.1016/j.canlet.2006.10.010 · Cited by 66
“A similar C-terminal truncation, resulting from alternative splicing, has been identified in many patients with t(8;21)-positive AML [28].”
BackgroundPulikkan, J. A., Madera, D., Xue, L., Bradley, P. J., Landrette, S. F., Kuo, Y., Abbas, S., Zhu, L. J., Valk, P. J. M., & Castilla, L. H. (2012) · Blood · doi:10.1182/blood-2012-03-414649 · Cited by 61
Li, Y., Wang, H., Wang, X., Jin, W. Y., Tan, Y., Fang, H., Chen, S., Zhu, C. H., & Wang, K. (2015) · Blood · doi:10.1182/blood-2015-03-626671 · Cited by 56
“Furthermore,AML1/ETO9a, an alternatively spliced isoform of AML1/ETO that has a lower capacity to inhibit wild-type AML1 activity,(18) shows a stronger leukemogenic potential in mice.(19) In addition to the functional importance of wild-type AML1 in t(8;21) AML, evidence from several high-throughput binding site studi…”
BackgroundImplication of the Molecular Characterization of Acute Myeloid Leukemia
Döhner, H. (2007) · Hematology · doi:10.1182/asheducation-2007.1.412 · Cited by 57
“Candidates include secondary cytogenetic abnormalities, for example, trisomy 22 in patients with inv(16)/t(16;16); various gene mutations (see below); or the relative amount of an alternatively spliced isoform of the RUNX1-RUNX1T1 fusion transcript in patients with t(8;21).(43) The study of secondary gene mutations in…”
BackgroundOancea, C., Rüster, B., Henschler, R., Puccetti, E., & Ruthardt, M. (2010) · Leukemia · doi:10.1038/leu.2010.180 · Cited by 57
Wichmann, C. W., Coco, I. Q.-L., Yildiz, Ö., Chen-Wichmann, L., Weber, H., Syzonenko, T., Döring, C., Brendel, C., Ponnusamy, K., Kinner, A., et al. (2014) · Leukemia · doi:10.1038/leu.2014.179 · Cited by 54
Yan, M., Ahn, E.-Y. E., Hiebert, S. W., & Zhang, D. (2008) · Blood · doi:10.1182/blood-2008-04-153742 · Cited by 55
Self-citationAML1/ETO and its function as a regulator of gene transcription via epigenetic mechanisms
Rejeski, K., Duque‐Afonso, J., & Lübbert, M. (2021) · Oncogene · doi:10.1038/s41388-021-01952-w · Cited by 60
Dimer-tetramer transition controls RUNX1/ETO leukemogenic activity
Wichmann, C. W., Becker, Y., Chen-Wichmann, L., Vogel, V., Vojtkova, A., Herglotz, J., Moore, S., Koch, J., Lausen, J., Mäntele, W., et al. (2010) · Blood · doi:10.1182/blood-2009-10-248047 · Cited by 55
“14 RUNX1/ETOtr dimers fail to induce leukemia in mice In contrast to full length RUNX1/ETO, the truncated form of the oncoprotein (REtr) has been shown to induce leukemia in mice.(3,4,13) To evaluate the relevance of tetramer versus dimer formation for the transformation capability of RUNX1/ETO we transduced lineage d…”
BackgroundReview: genetic models of acute myeloid leukaemia
McCormack, E., Bruserud, Ø., & Gjertsen, B. T. (2008) · Oncogene · doi:10.1038/onc.2008.16 · Cited by 57
“, 2003) AML1-ETO AML1-ETO9a Foetal liver cells Anaemia, high WBC with abnormal differentiation counts, cachexia AML without maturation (100%) (Yan et al., 2006)”
BackgroundMEIS2 Is an Oncogenic Partner in AML1-ETO-Positive AML
Naidu, V. M., Klappacher, J., Oswald, F., Mulaw, M. A., Mandoli, A., Thiel, V. N., Bamezai, S., Feder, K., Martens, J. H. A., Rawat, V. P. S., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.05.094 · Cited by 52
“However, we did not see acceleration of AE9a induced disease by MEIS2 co-expression, in line with published data demonstrating rapid onset of leukemia by AE9a alone in contrast to the full-length AE fusion (Yan et al., 2006).”
Kwok, C., Zeisig, B. B., Qiu, J. J., Dong, S., & So, C. W. E. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810558106 · Cited by 51
“Consistently, the recently identified oncogenic spliced isoform AE9a (14), with deletion of both NHR3 and NHR4 could still form third and subsequent rounds of colonies (Fig.”
BackgroundAhn, E.-Y., Yan, M., Malakhova, O. A., Lo, M., Boyapati, A., Ommen, H. B., Hines, R., Hokland, P., & Zhang, D. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802696105 · Cited by 47
“GST-SON (1-81) WT WT C663S C663S Lysates IP : Flag”
BackgroundMethodInfluentialSelf-citationSalat, D., Liefke, R., Wiedenmann, J., Borggrefe, T., & Oswald, F. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01966-07 · Cited by 54
“To examine the subcellular localization of SHARP, ETO, and AML1/ETO, HEK293 cells were cotransfected with eGFP fusions of ETO, AML1/ETO, and a recently identified C-terminally truncated version of AML1/ETO (46), together with full-length SHARP (see Fig.”
BackgroundMethodWichmann, C. W., Chen, L., Heinrich, M., Baus, D., Pfitzner, E., Zörnig, M., Ottmann, O. G., & Grez, M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3360 · Cited by 51
“Also, recent studies have shown that truncated forms of RUNX1/ETO, which lack the COOH-terminal N-CoR and SMRT binding domains, but still include the NHR2 sequences, have significant transforming potential (19, 39).”
BackgroundEriksson, M., Peña‐Martínez, P., Ramakrishnan, R., Chapellier, M., Högberg, C., Glowacki, G., Orsmark‐Pietras, C., Velasco-Hernández, T., Lazarević, V., Juliusson, G., et al. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017006148 · Cited by 47
“Similarly, mouse AML1-ETO9a leukemias were previously generated by retroviral expression of AML1-ETO9a along with EGFP in HSPCs.(26,27) Leukemia cells were propagated by transplantation into sublethally irradiated (600 cGy) C57BL/6 mice recipients.”
InfluentialGao, X., Lin, J., Gao, L., Deng, A., Lu, X., Li, Y., Wang, L., & Yu, L. (2015) · PLoS ONE · doi:10.1371/journal.pone.0124241 · Cited by 43
“Especially, AML1/ETO9a, a spliced isoform of AML1/ETO [29], correlates with c-kit overexpression/mutations and indicates poor disease outcome in the FAB-M2 subtype of t(8;21) AML [30].”
BackgroundChen, X., Zheng, J., Zou, Y., Song, C. X., Hu, X., & Zhang, C. C. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-72 · Cited by 43
“Human embryonic kidney 293 T cells were grown in DMEM with 10% fetal bovine serum (FBS) and transfected with an MSCV-AML1-ETO9a-IRES-GFP encoding plasmid [38] and pCL-ECO to produce retroviruses.”
BackgroundMethodInfluential
Metadata
- Authors
- Yan, M., Kanbe, E., Peterson, L. F., Boyapati, A., Miao, Y., Wang, Y., Chen, I.-M., Chen, Z., Rowley, J. D., Willman, C. L., & Zhang, D.-E.
- Affiliations
- Scripps Research Institute (US)
- University of New Mexico (US)
- Soochow University (CN)
- University of Chicago (US)
- Corresponding author
- Zhang, Dong-Er
- Venue
- Nature Medicine
- Published
- 2006-07-30
- Volume
- 12
- Issue
- 8
- Pages
- 945-949
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2038583094
- Cited by
- 279
- References
- 30
- Citations by year
- 2026: 6 · 2025: 8 · 2024: 14 · 2023: 17 · 2022: 6 · 2021: 9 · 2020: 11 · 2019: 16 · 2018: 15 · 2017: 19 · 2016: 16 · 2015: 18 · 2014: 13 · 2013: 18 · 2012: 16
- FWCI
- 9.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Heart, Lung, and Blood Institute (F32HL079900)
- National Cancer Institute (CA 104509, R01CA096735, CA096735, R01CA104509)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Research and Splicing
- Keywords
- AML1-ETO fusion protein, alternative splicing, RUNX1, RUNX1T1, acute myeloid leukemia, leukemogenesis, myeloid differentiation
- MeSH terms
- RUNX1 Translocation Partner 1 Protein, Amino Acid Sequence, Animals, Cell Line, Chromosomes, Human, Pair 21, Chromosomes, Human, Pair 8, Disease Models, Animal, Exons, Humans, Mice, Inbred C57BL, Mice, Inbred Strains, Mice, Transgenic, Molecular Sequence Data, Neoplasm Transplantation, Retroviridae, Translocation, Genetic, Leukemia, Myeloid, Acute, Oncogene Proteins, Fusion, Alternative Splicing, Protein Structure, Tertiary, Jurkat Cells, Protein Isoforms, Core Binding Factor Alpha 2 Subunit, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.